Bal Pharma Past Earnings Performance

Past criteria checks 5/6

Bal Pharma has been growing earnings at an average annual rate of 41.1%, while the Pharmaceuticals industry saw earnings growing at 17% annually. Revenues have been growing at an average rate of 11.9% per year. Bal Pharma's return on equity is 10.8%, and it has net margins of 2.2%.

Key information

41.1%

Earnings growth rate

40.6%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate11.9%
Return on equity10.8%
Net Margin2.2%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Bal Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:524824 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 243,392746040
31 Dec 233,270356010
30 Sep 233,220325890
30 Jun 233,048245710
31 Mar 233,042265610
31 Dec 222,958295420
30 Jun 222,802434940
31 Mar 222,812564780
31 Dec 212,780724590
30 Jun 212,692594260
31 Mar 212,505474260
31 Dec 202,135-344250
30 Sep 201,936-734380
30 Jun 201,741-954690
31 Mar 201,711-1225080
31 Dec 191,924-525290
30 Sep 192,081-155370
30 Jun 192,206-215190
31 Mar 192,250385190
31 Dec 182,264295790
31 Mar 182,093285430
31 Dec 172,111144870
31 Mar 172,289184710
31 Dec 162,210-34550
30 Sep 162,120134310
30 Jun 162,016163960
31 Mar 161,983143870
31 Dec 151,9594758012
30 Sep 151,9253356712
30 Jun 151,861293270
31 Mar 151,875363360
31 Dec 141,846485429
30 Sep 141,857545359
30 Jun 141,836512920
31 Mar 141,789515129
31 Dec 131,720584448
30 Sep 131,631554338

Quality Earnings: 524824 has high quality earnings.

Growing Profit Margin: 524824's current net profit margins (2.2%) are higher than last year (0.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 524824's earnings have grown significantly by 41.1% per year over the past 5 years.

Accelerating Growth: 524824's earnings growth over the past year (187.4%) exceeds its 5-year average (41.1% per year).

Earnings vs Industry: 524824 earnings growth over the past year (187.4%) exceeded the Pharmaceuticals industry 18%.


Return on Equity

High ROE: 524824's Return on Equity (10.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.